Novo Nordisk price target lowered to DKK 600 from DKK 700 at Morgan Stanley
Morgan Stanley analyst Thibault Boutherin lowered the firm’s price target on Novo Nordisk (NVO) to DKK 600 from DKK 700 and keeps an Equal ...
Novo Nordisk says copycat compounders are hurting Wegovy sales, may take legal action
Novo Nordisk said Thursday that the rampant growth of the U.S.’ compounded drug industry was hurting Wegovy sales, and warned ...
Novo shares on track for biggest monthly fall since 2002, investor worries grow
Novo Nordisk shares have fallen 25% so far in March and are on track for their biggest monthly drop since July 2002, as ...
Novo Nordisk-Minnesota deal to settle insulin lawsuit approved
A U.S. federal judge approves a deal between Novo Nordisk (NVO) and Minnesota that settled a lawsuit over high insulin prices ...
Healthy Returns: Novo Nordisk scoops up Chinese obesity drug to compete with Eli Lilly
Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...
Novo Nordisk Signs $2 Billion Deal for Experimental Obesity Drug
Novo Nordisk agreed to pay up to $2 billion for the rights to a developmental weight-loss and obesity drug from Chinese ...